Literature DB >> 20938004

Use of retinal procedures in medicare beneficiaries from 1997 to 2007.

Pradeep Y Ramulu1, Diana V Do, Kevin J Corcoran, Suzanne L Corcoran, Alan L Robin.   

Abstract

OBJECTIVE: To observe how the treatment of retinal conditions changed over the preceding decade.
METHODS: Medicare fee-for-service data claims filed between 1997 and 2007 were analyzed.
RESULTS: Fewer than 5000 intravitreal injections of a pharmacological agent were performed annually between 1997 and 2001. Thereafter, the annual number of intravitreal injections more than doubled every year through 2006, reaching a high of 812,413 in 2007. Photodynamic therapy procedures decreased 83% from a peak of 133,565 procedures in 2004 to 22,675 procedures in 2007, while laser treatment of choroidal lesions or neovascularization decreased 83% from a peak of 82,089 in 1999 to a minimum of 13,821 in 2007. Vitrectomies for primary retinal detachment (with or without scleral buckling) increased 72% over the study period from 11,212 in 1997 to 19,923 in 2007, while scleral buckles performed without vitrectomy decreased 69% from 8691 to 2660. Substantial volume increases were also observed for vitrectomy with retinal membrane stripping (90% increase from 29,426 in 1997 to 56,051 in 2007) or endolaser panretinal photocoagulation (86% increase from 10,319 in 1997 to 19,154 in 2007). Volumes of pneumatic retinopexy, laser prophylaxis for retinal detachment, laser treatment for retinal edema, and laser treatment for retinopathy all changed less than 25% from 1997 and 2007.
CONCLUSIONS: Marked changes in the use of several retinal procedures occurred between 1997 and 2007, particularly in the treatment of macular degeneration and retinal detachment. These changes point to greater acceptance and incorporation of vitrectomy and intravitreal injection as treatment modalities.

Entities:  

Mesh:

Year:  2010        PMID: 20938004     DOI: 10.1001/archophthalmol.2010.224

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  22 in total

1.  Scleral buckling versus vitrectomy: can the trend be reversed suprachoroidally?

Authors:  David Wong; Lara Sandri; David H W Steel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-11-16       Impact factor: 3.117

2.  Trends in Medicare Service Volume for Cataract Surgery and the Impact of the Medicare Physician Fee Schedule.

Authors:  Dan Gong; Lin Jun; James C Tsai
Journal:  Health Serv Res       Date:  2016-07-28       Impact factor: 3.402

3.  Medicare costs for neovascular age-related macular degeneration, 1994-2007.

Authors:  Shelley Day; Kofi Acquah; Paul P Lee; Prithvi Mruthyunjaya; Frank A Sloan
Journal:  Am J Ophthalmol       Date:  2011-08-16       Impact factor: 5.258

4.  Unexpected Roles for Toll-Like Receptor 4 and TRIF in Intraocular Infection with Gram-Positive Bacteria.

Authors:  Salai Madhumathi Parkunan; C Blake Randall; Phillip S Coburn; Roger A Astley; Rachel L Staats; Michelle C Callegan
Journal:  Infect Immun       Date:  2015-07-20       Impact factor: 3.441

5.  Culture-Proven Endophthalmitis After Intravitreal Injection: A 10-Year Analysis.

Authors:  Joseph M Simonett; Austin Igelman; Stanford C Taylor; J Peter Campbell; Thomas S Hwang; Phoebe Lin; Andreas K Lauer; Christina J Flaxel
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-01-01       Impact factor: 1.300

Review 6.  Use of health care claims data to study patients with ophthalmologic conditions.

Authors:  Joshua D Stein; Flora Lum; Paul P Lee; William L Rich; Anne L Coleman
Journal:  Ophthalmology       Date:  2014-01-14       Impact factor: 12.079

7.  United Kingdom National Ophthalmology Database Study of Vitreoretinal Surgery: report 1; case mix, complications, and cataract.

Authors:  T L Jackson; P H J Donachie; J M Sparrow; R L Johnston
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

8.  Endophthalmitis Associated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.

Authors:  Stephen G Schwartz; Harry W Flynn
Journal:  Curr Ophthalmol Rep       Date:  2014-03-01

9.  Reduced fluorescein angiography and fundus photography use in the management of neovascular macular degeneration and macular edema during the past decade.

Authors:  Eric W Schneider; Prithvi Mruthyunjaya; Nidhi Talwar; Kristen Harris Nwanyanwu; Bin Nan; Joshua D Stein
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-29       Impact factor: 4.799

Review 10.  Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents.

Authors:  Ravi S J Singh; Judy E Kim
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.